Mandy Jackson

Executive Summary Highlights will include data for Summit/Akeso's PD-L1/VEGF bispecific versus Keytruda, ADCs and DLL3-targeting drugs for SCLC, and agents against EGFR, HER2 and Trop-2 in NSCLC.

Executive Summary Fifteen biopharma firms have launched IPOs in the US this year, but three more have joined the queue.

Executive Summary The company's VAX-31 against 31 pneumococcal serotypes outperformed Pfizer's market-leading Prevnar 20 and could provide the broadest coverage of any vaccine in its class.

Executive Summary The company said that while its drug did not achieve statistical significance on any endpoints in the Alzheimer's study, improvements favoring fosgonimeton showed potential for HGF modulation.

Executive Summary ArsenalBio closed one of the largest VC rounds so far in 2024, raising $325m in series C funding, while Vaxcyte grossed $1.3bn in a follow-on offering.

Executive Summary Survival and other benefits with J&J's EGFR/MET inhibitor Rybrevant plus EGFR inhibitor Lazcluze relative to AstraZeneca's Tagrisso in first-line EGFR-mutant NSCLC continued to improve at 31.1 months.

Data at WCLC showed why the TROP2-targeting ADC datopotamab deruxtecan is most effective in non-squamous NSCLC in second or later lines as presented in overall survival data at the meeting.

Boehringer presented Phase Ib results for zongertinib and Bayer presented Phase I/II results for BAY 2927088 in NSCLC with HER2 mutations – a rare cancer with ADC Enhertu as a major competitor – at the WCLC meeting.

Executive Summary Newly public company ArriVent BioPharma presented Phase Ib results at WCLC for its kinase inhibitor, which could be the first drug available specifically for hard-to-treat PACC mutations.

Executive Summary Private Company Edition: Bain will invest across private and public drug, device, diagnostic and tool companies.